checkAd

     165  0 Kommentare Materialise Reports First Quarter 2023 Results

    Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the first quarter ended March 31, 2023.

    Highlights – First Quarter 2023

    • Total revenue increased 24.4% to 65,886 kEUR compared to 52,961 kEUR for the first quarter of 2022.
    • Total deferred revenues from annual software sales and maintenance fees increased by 1,728 kEUR this quarter to 44,508 kEUR.
    • Adjusted EBITDA increased to 10,310 kEUR for the first quarter of 2023 from 5,443 kEUR for the 2022 period.
    • Net profit for the first quarter of 2023 was 3,715 kEUR, or 0.06 EUR per diluted share, compared to 127 kEUR, or 0.00 EUR per diluted share, for the 2022 period.

    Executive Chairman Peter Leys commented, “Materialise performed extremely well in the year’s opening quarter. Our consolidated revenues increased more than 24%, boosted by the very strong growth of Materialise Medical and Materialise Manufacturing revenues, by 33% and 25% respectively, and further supported by a solid revenue uptake at Materialise Software of more than 8%. During the quarter, our Adjusted EBITDA increased 89% to 10,310 kEUR, mainly because of scaling effects.”

    First Quarter 2023 Results

    Total revenue for the first quarter of 2023 increased 24.4% to 65,886 kEUR from 52,961 kEUR for the first quarter of 2022. Adjusted EBITDA increased to 10,310 kEUR for the first quarter of 2023 from 5,443 kEUR for the 2022 period. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the first quarter of 2023 was 15.6%, compared to 10.3% for the first quarter of 2022.

    Revenue from Materialise Software increased 8.3% to 11,350 kEUR for the first quarter of 2023 from 10,483 kEUR for the same quarter last year. Segment Adjusted EBITDA increased to 2,427 kEUR from 1,932 kEUR while the segment Adjusted EBITDA margin was 21.4% compared to 18.4% for the prior-year period.

    Revenue from our Materialise Medical segment increased 32.5% to 24,317 kEUR for the first quarter of 2023 compared to 18,347 kEUR for the same period in 2022. Segment Adjusted EBITDA increased to 7,348 kEUR for the first quarter of 2023 compared to 3,227 kEUR while the segment Adjusted EBITDA margin grew to 30.2% compared to 17.6% for the first quarter of 2022.

    Revenue from our Materialise Manufacturing segment increased 25.2% to 30,219 kEUR for the first quarter of 2023 from 24,131 kEUR for the first quarter of 2022. Segment Adjusted EBITDA increased to 3,189 kEUR from 2,613 kEUR while the segment Adjusted EBITDA margin was 10.6% compared to 10.8% for the first quarter of 2022.

    Gross profit grew to 36,837 kEUR compared to 28,884 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 55.9% compared to 54.5% for the first quarter of 2022.

    Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 8.7% to 32,358 kEUR for the first quarter of 2023 from 29,774 kEUR for the first quarter of 2022.

    Net other operating income was 519 kEUR compared to 938 kEUR for the first quarter of 2022.

    Operating result amounted to 4,998 kEUR compared to 49 kEUR for the first quarter of 2022.

    Net financial result was (566) kEUR compared to 376 kEUR for the first quarter of 2022.

    The first quarter of 2023 contained income tax expenses of (718) kEUR, compared to (298) kEUR in the first quarter of 2022.

    As a result of the above, net profit for the first quarter of 2023 was 3,715 kEUR, compared to 127 kEUR for the same period in 2022. Total comprehensive income for the first quarter of 2023, which includes exchange differences on translation of foreign operations, was 4,490 kEUR compared to 1,543 kEUR for the 2022 period.

    At March 31, 2023, we had cash and cash equivalents of 141,720 kEUR compared to 140,867 kEUR at December 31, 2022. Gross debt amounted to 75,251 kEUR, compared to 80,980 kEUR at December 31, 2022. As a result, our net cash position (gross debt less cash and cash equivalents) increased 6,582 kEUR to 66,469 kEUR.

    Cash flow from operating activities for the first quarter of 2023 decreased to 11,044 kEUR from 11,111 kEUR for the same period in 2022. Total capital expenditures for the first quarter of 2023 amounted to 3,271 kEUR.

    Net shareholders’ equity at March 31, 2023 was 233,251 kEUR compared to 228,928 kEUR at December 31, 2022.

    2023 Guidance

    Executive Chairman Peter Leys concluded, “In the beginning of 2023, we expected Materialise to report consolidated revenue between 255,000 kEUR and 260,000 kEUR and Adjusted EBITDA between 25,000 kEUR and 30,000 kEUR. Based on the company’s strong Q1 performance, but also bearing in mind the uncertain global macro-economic environment, we now believe that our 2023 revenue will come closer to the high end of the initially guided range, and expect that our 2023 Adjusted EBITDA could be up to 10% higher than the top of the range communicated earlier.”

    Non-IFRS Measures

    Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

    Exchange Rate

    This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.0875, the reference rate of the European Central Bank on March 31, 2023.

    Conference Call and Webcast

    Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2023 on Thursday, April 27, 2023, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Wilfried Vancraen, Founder and Chief Executive Officer; Peter Leys, Executive Chairman; and Johan Albrecht, Chief Financial Officer. A question-and-answer session will follow management’s remarks.

    To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call.

    The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website.

    About Materialise

    Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

    Cautionary Statement on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our current estimates for fiscal 2023 revenue and Adjusted EBITDA, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the ongoing military conflict between Ukraine and Russia and economic sanctions related thereto as well as by inflation and increased labor, energy and materials costs), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release.

    The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

    Consolidated income statements (Unaudited)

     
    for the three months ended
    March 31,
    In '000

    2023

    2023

    2022

    U.S.$
    Revenue

    71,651

    65,886

    52,961

    Cost of Sales

    (31,591)

    (29,049)

    (24,078)

    Gross Profit

    40,060

    36,837

    28,884

    Gross profit as % of revenue

    55.9%

    55.9%

    54.5%

     
    Research and development expenses

    (9,802)

    (9,014)

    (7,814)

    Sales and marketing expenses

    (15,539)

    (14,288)

    (13,515)

    General and administrative expenses

    (9,848)

    (9,056)

    (8,444)

    Net other operating income (expenses)

    565

    519

    938

    Operating (loss) profit

    5,436

    4,998

    49

     
    Financial expenses

    (1,495)

    (1,375)

    (1,289)

    Financial income

    880

    809

    1,665

    Share in loss of joint venture

    -

    -

    -

    (Loss) profit before taxes

    4,821

    4,432

    425

     
    Income Taxes

    (780)

    (718)

    (298)

    Net (loss) profit for the period

    4,041

    3,715

    127

    Net (loss) profit attributable to:

    -

    The owners of the parent

    4,047

    3,721

    134

    Non-controlling interest

    (7)

    (7)

    (7)

     
    Earning per share attributable to owners of the parent
    Basic

    0.07

    0.06

    0.00

    Diluted

    0.07

    0.06

    0.00

     
    Weighted average basic shares outstanding

    59,067

    59,067

    59,064

    Weighted average diluted shares outstanding

    59,070

    59,070

    59,102

    Consolidated statements of comprehensive income (Unaudited)

     
    for the three months ended
    March 31,
    In 000€

    2023

    2023

    2022

    U.S.$
    Net profit (loss) for the period

    4,041

    3,715

    127

    Other comprehensive income
    Recycling
    Exchange difference on translation of foreign operations

    843

    776

    1,416

    Non-recycling
    Fair value adjustments through OCI - Equity instruments

    -

    -

    -

    Other comprehensive income (loss), net of taxes

    843

    776

    1,416

    Total comprehensive income (loss) for the year, net of taxes

    4,883

    4,490

    1,543

    Total comprehensive income (loss) attributable to:
    The owners of the parent

    4,890

    4,496

    1,549

    Non-controlling interests

    (6)

    (6)

    (7)

    Consolidated statement of financial position (Unaudited)

     
    As of
    March 31,
    As of
    December 31,
    In 000€

    2023

    2022

    Assets
    Non-current assets
    Goodwill

    44,196

    44,155

    Intangible assets

    36,944

    37,875

    Property, plant & equipment

    94,462

    94,276

    Right-of-Use assets

    8,323

    8,420

    Investments in joint ventures

    -

    -

    Deferred tax assets

    1,208

    1,186

    Investments in convertible loans

    3,555

    3,494

    Investments in non-listed equity instruments

    307

    307

    Other non-current assets

    5,414

    5,136

    Total non-current assets

    194,409

    194,847

    Current assets
    Inventories

    15,810

    16,081

    Trade receivables

    47,780

    51,043

    Other current assets

    8,114

    8,424

    Cash and cash equivalents

    141,720

    140,867

    Total current assets

    213,423

    216,414

    Total assets

    407,833

    411,262

    As of
    March 31,
    As of
    December 31,
    In 000€

    2023

    2022

    Equity and liabilities
    Equity
    Share capital

    4,487

    4,487

    Share premium

    233,895

    233,895

    Retained earnings and other reserves

    (5,097)

    (9,427)

    Equity attributable to the owners of the parent

    233,285

    228,955

    Non-controlling interest

    (34)

    (28)

    Total equity

    233,251

    228,928

    Non-current liabilities
    Loans & borrowings

    51,035

    55,873

    Lease liabilities

    4,964

    5,147

    Deferred tax liabilities

    4,167

    4,312

    Deferred income

    8,858

    9,277

    Other non-current liabilities

    504

    1,611

    Total non-current liabilities

    69,528

    76,220

    Current liabilities
    Loans & borrowings

    16,328

    17,058

    Lease liabilities

    2,924

    2,902

    Trade payables

    23,776

    23,230

    Tax payables

    1,922

    1,246

    Deferred income

    43,474

    41,721

    Other current liabilities

    16,630

    19,957

    Total current liabilities

    105,054

    106,114

    Total equity and liabilities

    407,833

    411,262

    Consolidated statement of cash flows (Unaudited)

     
    for the three months ended
    March 31,
    In 000€

    2023

    2022

    Operating activities
    Net (loss) profit for the period

    3,715

    127

    Non-cash and operational adjustments
    Depreciation of property plant & equipment

    3,637

    3,840

    Amortization of intangible assets

    1,674

    1,602

    Impairment of goodwill and intangible assets

    -

    -

    Share-based payment expense

    -

    (48)

    Loss (gain) on disposal of intangible assets and property, plant & equipment

    (22)

    (18)

    Movement in provisions

    (618)

    2

    Movement reserve for bad debt and slow moving inventory

    109

    130

    Financial income

    (767)

    (1,618)

    Financial expense

    1,375

    1,237

    Impact of foreign currencies

    6

    (28)

    (Deferred) income taxes

    717

    302

    Working capital adjustments

    850

    5,923

    Decrease (increase) in trade receivables and other receivables

    3,363

    4,506

    Decrease (increase) in inventories and contracts in progress

    262

    (1,357)

    Increase (decrease) in deferred revenue

    1,368

    3,665

    Increase (decrease) in trade payables and other payables

    (4,142)

    (891)

    Income tax paid & Interest received

    367

    (341)

    Net cash flow from operating activities

    11,044

    11,111

    for the three months ended
    March 31,
    In 000€

    2023

    2022

    Investing activities
    Purchase of property, plant & equipment

    (2,532)

    (2,376)

    Purchase of intangible assets

    (738)

    (1,123)

    Proceeds from the sale of property, plant & equipment & intangible assets (net)

    100

    93

    Acquisition of subsidiary (net of cash)

    -

    (27,414)

    Net cash flow used in investing activities

    (3,171)

    (30,820)

    Financing activities
    Repayment of loans & borrowings

    (5,635)

    (5,969)

    Repayment of leases

    (859)

    (881)

    Interest paid

    (417)

    (515)

    Other financial income (expense)

    (108)

    (89)

    Net cash flow from (used in) financing activities

    (7,019)

    (7,452)

    Net increase/(decrease) of cash & cash equivalents

    854

    (27,161)

    Cash & Cash equivalents at the beginning of the year

    140,867

    196,028

    Exchange rate differences on cash & cash equivalents

    (1)

    743

    Cash & cash equivalents at end of the period

    141,720

    169,610

    Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

     
    for the three months ended
    March 31,
    In 000€

    2023

    2022

    Net profit (loss) for the period

    3,715

    127

    Income taxes

    718

    298

    Financial expenses

    1,375

    1,289

    Financial income

    (809)

    (1,665)

    Depreciation and amortization

    5,311

    5,442

    EBITDA

    10,310

    5,491

    Share-based compensation expense (1)

    -

    (48)

    Adjusted EBITDA

    10,310

    5,443

    (1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

    Segment P&L (Unaudited)

     
    In 000€ Materialise
    Software
    Materialise
    Medical
    Materialise
    Manufacturing
    Total
    segments
    Unallocated (1) Consolidated
    For the three months ended March 31, 2023
    Revenues

    11,350

    24,317

    30,219

    65,886

    0

    65,886

    Segment (adj) EBITDA

    2,427

    7,348

    3,189

    12,964

    (2,655)

    10,310

    Segment (adj) EBITDA %

    21.4%

    30.2%

    10.6%

    19.7%

    15.6%

    For the three months ended March 31, 2022
    Revenues

    10,483

    18,347

    24,131

    52,961

    0

    52,961

    Segment (adj) EBITDA

    1,932

    3,227

    2,613

    7,772

    (2,329)

    5,443

    Segment (adj) EBITDA %

    18.4%

    17.6%

    10.8%

    14.7%

    10.3%

    (1)

    Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.

    Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)

     
    for the three months ended
    March 31,
    In 000€

    2023

    2022

    Net profit (loss) for the period  

    3,715

     

    127

    Income taxes

    718

    298

    Financial cost  

    1,375

     

    1,289

    Financial income

    (809)

    (1,665)

    Operating (loss) profit  

    4,998

     

    49

    Depreciation and amortization

    5,311

    5,442

    Corporate research and development  

    722

     

    816

    Corporate headquarter costs

    2,640

    2,106

    Other operating income (expense)   

    (707)

     

    (640)

    Segment adjusted EBITDA

    12,964

    7,772

     


    The Materialise Stock at the time of publication of the news with a raise of +0,69 % to 7,25EUR on Tradegate stock exchange (27. April 2023, 12:33 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Materialise Reports First Quarter 2023 Results Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the first quarter ended March 31, 2023. Highlights – First Quarter …